Marc Elia, Chairman of the Board of Directors at Invivyd, discusses Pemgarda (pemivibart) for emergency use as a pre-exposure prophylactic therapy for prevention of COVID-19 infection in patients with compromised immune systems.
As Mr. Elia explains, COVID-19 is in an endemic phase and still relevant to the health of those in the United States. While vaccines provide an adequate level of defense against the illness for most, those with medical conditions affecting the immune system or on immunosuppressive treatments, are still at great risk of catching the illness and suffering from more serious symptoms.
Pemivibart is a monoclonal antibody that has been approved for Emergency Use Authorization by the U.S. Food and Drug Administration (FDA). The treatment has been authorized for pre-exposure prophylaxis of COVID-19 in adults and adolescents (ages 12 or older weighing at least 40 kg). It is intended for those with a medical condition resulting in immune compromise or those who are on immunosuppressive medications, who are likely to have an inadequate response to the COVID-19 vaccination.
Click here for the updated Fact Sheet for Healthcare Providers.
To learn more about rare diseases, visit https://checkrare.com/
